Generic glatiramer acetate — a step toward cheaper MS drugs?
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
A randomized, double-blind, phase III trial of generic glatiramer acetate has shown equivalent efficacy and safety compared with the approved formulation, Copaxone. The impact of approval of
generic glatiramer acetate, however, will mainly depend on the pricing of the drug.
The author's department has received research support from the Danish Multiple Sclerosis Society, the Danish Medical Research Council, and the European Union Sixth Framework Programme: Life
sciences, Genomics and Biotechnology for Health.
Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet, University of Copenhagen, Copenhagen, 2100, Denmark
The author has received personal compensation for serving on scientific advisery boards, steering committees or independent data-monitoring boards for Biogen Idec, Merck Serono, Novartis,
Genzyme, Teva Pharmaceutical Industries, GlaxoSmithKline, MedDay Pharmaceuticals and Forward Pharma, and has received speaker honouraria from Biogen Idec, Merck Serono, Teva Pharmaceutical
Industries, Genzyme and Novartis. His department has received research support from Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, Baxter, Sanofi Aventis, Novartis, Bayer, RoFAR,
Roche and Genzyme.
Anyone you share the following link with will be able to read this content: